Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC

EGFR mutant non-small cell lung cancer patients' disease demonstrates remarkable responses to EGFR-targeted therapy, but inevitably they succumb to acquired resistance, which can be complex and difficult to treat. Analyzing acquired resistance through broad molecular testing is crucial to under...

Descripción completa

Detalles Bibliográficos
Autores principales: Peters, T. L., Patil, T., Le, A. T., Davies, K. D., Brzeskiewicz, P. M., Nijmeh, H., Bao, L., Camidge, D. R., Aisner, D. L., Doebele, R. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511249/
https://www.ncbi.nlm.nih.gov/pubmed/34642436
http://dx.doi.org/10.1038/s41698-021-00231-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511249/
https://www.ncbi.nlm.nih.gov/pubmed/34642436
http://dx.doi.org/10.1038/s41698-021-00231-x

Ejemplares similares